Webull rises after better-than-expected second-quarter results

Shares of Webull Corp (NASDAQ: BULL ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results.

Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Pro.

The brokerage platform company posted second-quarter adjusted earnings of five cents per share, beating estimates of 3 cents per share.

Webull shares jumped 13.7% to $9.82 in pre-market trading.

Here are some other stocks moving in pre-market trading.

Gainers Reitar Logtech Holdings Ltd (NASDAQ: RITR ) gained 179% to $0.21 in pre-market trading after declining more than 5% on Wednesday.

BTC Digital Ltd (NASDAQ: BTCT ) rose 105.6% to $1.72 in pre-market trading after jumping 75% on Wednesday.

Loop Industries Inc (NASDAQ: LOOP ) rose 79% to $1.11 in pre-market trading.

The company disclosed in a Form8 filing that it granted ELITe non-transferable, perpetual, exclusive, royalty-bearing license to depolymerization technology and related intellectual property rights o build and operate licensed manufacturing facilities in India.

Beam Global (NASDAQ: BEEM ) rose 39.6% to $1.69 in pre-market trading after the company reported better-than-expected quarterly financial results.

Evaxion A/S (NASDAQ: EVAX ) rose 25.5% to $3.95 in pre-market trading.

Evaxion, recently, expanded and refocused R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program Megan Holdings Ltd (NASDAQ: MGN ) rose 54.4% to $0.16 in pre-market trading.

BioVie Inc (NASDAQ: BIVI ) rose 13.3% to $1.52 in pre-market trading after jumping 39% on Wednesday.

BioVie recently posted a fourth-quarter loss of 70 cents per share.

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) gained 11.2% to $29.19 in pre-market trading.

Ultragenyx announced the US FDA approval of GENGLYCOS gene therapy, the first-ever FDA-Approved treatment designed to treat the underlying cause of glycogen storage disease Type Ia (GSDIa).

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) shares gained 10% to $4.20 in pre-market trading.

Zentalis Pharmaceuticals recently announced the pricing of its $80.5 million proposed public offering of 23 million shares at $3.50 per share.

Losers Tenon Medical Inc (NASDAQ: TNON ) tumbled 30.7% to $7.92 in pre-market trading.

Tenon Medical shares jumped 109% on Wednesday after the company received a notice of allowance for a U.S.

Patent Titled “Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints.” Onfolio Holdings Inc (NASDAQ: ONFO ) fell 29.4% to $1.67 in pre-market trading after the company reported second-quarter 2026 results showing lower revenue and a wider loss.

OSR Health Inc (NASDAQ: OSRH ) declined 28.1% to $0.27 in pre-market trading.

OSR Health said it plans to request panel hearing after receiving Nasdaq delisting determination.

Surgepays Inc (NASDAQ: SURG ) fell 23.6% to $0.19 in pre-market trading.

SurgePays, on Friday, reported better-than-expected second-quarter financial results.

Matinas BioPharma Holdings Inc (NYSE: MTNB ) fell 22.1% to $0.19 in pre-market trading after gaining 18% on Wednesday.

Autozi Internet Technology (Global) Ltd (NASDAQ: AZI ) fell 19.3% to $1.34 in pre-market trading.

Autozi Internet Technology shares jumped 44% on Wednesday after the company announced that it has received an aggregate investment of $30 million from multiple investors.

Yunji Inc (NASDAQ: YJ ) fell 20.2% to $3.39 in pre-market trading after jumping 144% on Wednesday.

Moderna Inc (NASDAQ: MRNA ) fell 12.4% to $153.01 in pre-market trading.

Moderna shares jumped 177% on Wednesday after the company and Merck announced topline results from the Phase 3 INTerpath-001 trial met its primary and a key secondary endpoint.

Wolfspeed Inc (NYSE: WOLF ) fell 12% to $25.60 in pre-market trading after the company reported mixed fourth-quarter financial results.

Coty Inc (NYSE: COTY ) fell 7.7% to $2.80 in pre-market trading after the company reported mixed fourth-quarter financial results and issued first-quarter adjusted EPS guidance below estimates.

The company disclosed that the Gucci Beauty license exit will result in a step-down in FY28 sales and profit.

Photo via Shutterstock